Methods of treating endometriosis and other noncancer gynecological disorders with hemp extract

Patent metadata

Field	Value
Publication number	US-12409199-B2
Application number	US-202418639285-A
Country	US
Kind code	B2
Filing date	Apr 18, 2024
Priority date	Oct 26, 2021
Publication date	Sep 9, 2025
Grant date	Sep 9, 2025

Abstract

A method for treating a noncancerous gynecological disorder comprising: administering to a patient an effective amount of composition comprising a cannabis extract comprising cannabidiol (CBD) wherein the composition is preferably administered in a mucosal form, such as intravaginally.

First claim

What is claimed is:

1. A method of treating endometriosis, symptoms associated with endometriosis, or both, the method comprising administering an effective amount of a composition to a patient, said composition comprising a carrier of between 1% and 99% by weight, said composition comprising a cannabis extract (CE) wherein the CE comprises cannabidiol (CBD) from about 20% to about 99.9% by weight of the CE, the CBD extracted from a Cannabaceae plant as a full spectrum hemp extract (FSHE) or a broad spectrum hemp extract (BSHE), said CE delivered within the carrier to create the composition having a pH between 3.5 and 6.

2. The method of claim 1 wherein the CE is administered to the patient as an oral form, oromucosal form, nasal form, rectal form, intravaginal form, injectable form, or combinations thereof.

3. The method of claim 1 wherein the CE further comprises cannabidiolic acid (CBDA) at a concentration of between 0.1% and 10%.

4. The method of claim 1 wherein the effective amount of CE comprises between 25 mg and 4,250 mg of CBD per dose.

5. The method of claim 1 wherein the composition comprises at least one additional compound selected from the group consisting of: a terpene, a polyphenol, an essential fatty acid, a phytonutrient, and combinations thereof; and wherein the at least one additional compound makes up between 0.1% and 50% by weight of the composition.

6. The method of claim 1 wherein the CE is administered orally using an oil or a fat as the carrier.

7. The method of claim 1 further comprising administering the CE concomitantly with a second therapeutic agent.

8. The method of claim 7 wherein the second therapeutic agent is a hormone, gonadotrophin-releasing hormone, progestin, an aromatase inhibitor, a chemotherapeutic agent, or combinations thereof.

9. The method of claim 1 wherein the CE further comprises from about 0.01% to about 0.3% by weight of Δ-9-tetrahydrocannabinol (Δ 9 -THC).

10. The method of claim 1 wherein the CE comprises from about 70% to about 99.9% by weight of CBD.

11. The method of claim 1 wherein administering comprises administering orally up to three times per day.

Assignees

• Ecofibre Usa Inc
• Univ Newcastle

Inventors

• Capano Alexandra M
• Tanwar Pradeep Singh
• Nance Alex

Classifications

• A61K36/185 Primary

  Magnoliopsida (dicotyledons) · CPC title

• A61K36/3482 Primary

  Cannabis · CPC title

• A61K31/658

  o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol · CPC title

• A61K31/60

  Salicylic acid; Derivatives thereof · CPC title

• A61K31/353

  3,4-Dihydrobenzopyrans, e.g. chroman, catechin · CPC title